When A2AR blockade is combined with PD-1 inhibitors, it significantly reduces tumor progression and achieves partial or complete remission in patients with non-small cell lung cancer (NSCLC) (16). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.